Nicolas DuprÃ©

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1086646/publications.pdf

Version: 2024-02-01

77 papers	2,502 citations	218381 26 h-index	233125 45 g-index
83 all docs	83 docs citations	83 times ranked	4289 citing authors

#	Article	IF	Citations
1	Mutations in SYNE1 lead to a newly discovered form of autosomal recessive cerebellar ataxia. Nature Genetics, 2007, 39, 80-85.	9.4	287
2	Deleterious mutations in the essential mRNA metabolism factor, hGle1, in amyotrophic lateral sclerosis. Human Molecular Genetics, 2015, 24, 1363-1373.	1.4	122
3	From animal models to human disease: a genetic approach for personalized medicine in ALS. Acta Neuropathologica Communications, 2016, 4, 70.	2.4	115
4	Mutations in CAPN1 Cause Autosomal-Recessive Hereditary Spastic Paraplegia. American Journal of Human Genetics, 2016, 98, 1038-1046.	2.6	96
5	Misfolded SOD1 pathology in sporadic Amyotrophic Lateral Sclerosis. Scientific Reports, 2018, 8, 14223.	1.6	85
6	Clinical and genetic study of autosomal recessive cerebellar ataxia type 1. Annals of Neurology, 2007, 62, 93-98.	2.8	82
7	Clinical and genetic study of hereditary spastic paraplegia in Canada. Neurology: Genetics, 2017, 3, e122.	0.9	82
8	SMPD1 mutations, activity, and Î±â€synuclein accumulation in Parkinson's disease. Movement Disorders, 2019, 34, 526-535.	2.2	81
9	The Classification of Autosomal Recessive Cerebellar Ataxias: a Consensus Statement from the Society for Research on the Cerebellum and Ataxias Task Force. Cerebellum, 2019, 18, 1098-1125.	1.4	80
10	Hereditary motor and sensory neuropathy with agenesis of the corpus callosum. Annals of Neurology, 2003, 54, 9-18.	2.8	67
11	Genetic, Structural, and Functional Evidence Link TMEM175 to Synucleinopathies. Annals of Neurology, 2020, 87, 139-153.	2.8	65
12	Pompe Disease: Diagnosis and Management. Evidence-Based Guidelines from a Canadian Expert Panel. Canadian Journal of Neurological Sciences, 2016, 43, 472-485.	0.3	54
13	Replication study of MATR3 in familial and sporadic amyotrophic lateral sclerosis. Neurobiology of Aging, 2016, 37, 209.e17-209.e21.	1.5	53
14	RNF213 Is Associated with Intracranial Aneurysms in the French-Canadian Population. American Journal of Human Genetics, 2016, 99, 1072-1085.	2.6	49
15	Systematic review of autosomal recessive ataxias and proposal for a classification. Cerebellum and Ataxias, 2017, 4, 3.	1.9	49
16	SYNE1Mutations in Autosomal Recessive Cerebellar Ataxia. JAMA Neurology, 2013, 70, 1296-31.	4.5	47
17	Early detection of structural abnormalities and cytoplasmic accumulation of TDP-43 in tissue-engineered skins derived from ALS patients. Acta Neuropathologica Communications, 2015, 3, 5.	2.4	47
18	Clinical Validity of the Mattis Dementia Rating Scale-2 in Parkinson Disease With MCI and Dementia. Journal of Geriatric Psychiatry and Neurology, 2012, 25, 100-106.	1.2	45

#	Article	IF	Citations
19	Clinical, electrophysiologic, and genetic study of non-dystrophic myotonia in French-Canadians. Neuromuscular Disorders, 2009, 19, 330-334.	0.3	44
20	Canadian best practice recommendations for the management of amyotrophic lateral sclerosis. Cmaj, 2020, 192, E1453-E1468.	0.9	44
21	Evolution of a Human-Specific Tandem Repeat Associated with ALS. American Journal of Human Genetics, 2020, 107, 445-460.	2.6	39
22	Fineâ€Mapping of SNCA in Rapid Eye Movement Sleep Behavior Disorder and Overt Synucleinopathies. Annals of Neurology, 2020, 87, 584-598.	2.8	39
23	Analysis of Heterozygous <scp>PRKN</scp> Variants and Copyâ€Number Variations in Parkinson's Disease. Movement Disorders, 2021, 36, 178-187.	2.2	39
24	Analysis of DNAJC13 mutations in French-Canadian/French cohort of Parkinson's disease. Neurobiology of Aging, 2016, 45, 212.e13-212.e17.	1.5	38
25	The Quebec Parkinson Network: A Researcher-Patient Matching Platform and Multimodal Biorepository. Journal of Parkinson's Disease, 2020, 10, 301-313.	1.5	35
26	Targeted sequencing of Parkinsonâ€™s disease loci genes highlights SYT11, FGF20 and other associations. Brain, 2021, 144, 462-472.	3.7	31
27	Transmission of ALS pathogenesis by the cerebrospinal fluid. Acta Neuropathologica Communications, 2020, 8, 65.	2.4	30
28	Linkage to the CCM2 Locus and Genetic Heterogeneity in Familial Cerebral Cavernous Malformation. Canadian Journal of Neurological Sciences, 2003, 30, 122-128.	0.3	29
29	Teneurin transmembrane protein 4 is not a cause for essential tremor in a Canadian population. Movement Disorders, 2017, 32, 292-295.	2.2	29
30	Management of Patients with Cerebellar Ataxia During the COVID-19 Pandemic: Current Concerns and Future Implications. Cerebellum, 2020, 19, 562-568.	1.4	26
31	Moyamoya Disease Susceptibility Gene RNF213 Regulates Endothelial Barrier Function. Stroke, 2022, 53, 1263-1275.	1.0	26
32	Cognitive Impairment in ARCA-1, a Newly Discovered Pure Cerebellar Ataxia Syndrome. Cerebellum, 2010, 9, 443-453.	1.4	24
33	Effects of Antiparkinson Medication on Cognition in Parkinsonâ€™s Disease: A Systematic Review. Canadian Journal of Neurological Sciences, 2018, 45, 375-404.	0.3	24
34	Chemosensory Dysfunctions Induced by COVID-19 Can Persist up to 7 Months: A Study of Over 700 Healthcare Workers. Chemical Senses, 2021, 46, .	1.1	24
35	The Occurrence of FUS Mutations in Pediatric Amyotrophic Lateral Sclerosis: A Case Report and Review of the Literature. Journal of Child Neurology, 2020, 35, 556-562.	0.7	23
36	Characterization of the phenotype with cognitive impairment and protein mislocalization in SCA34. Neurology: Genetics, 2020, 6, e403.	0.9	21

#	Article	IF	Citations
37	Common and rare GCH1 variants are associated with Parkinson'sÂdisease. Neurobiology of Aging, 2019, 73, 231.e1-231.e6.	1.5	20
38	Clinical and genetic analysis of ATP13A2 in hereditary spastic paraplegia expands the phenotype. Molecular Genetics & Genomic Medicine, 2020, 8, e1052.	0.6	20
39	Analysis of common and rare VPS13C variants in late-onset Parkinson disease. Neurology: Genetics, 2020, 6, 385.	0.9	19
40	Association study of DNAJC13, UCHL1, HTRA2, GIGYF2, and EIF4G1 with Parkinson's disease. Neurobiology of Aging, 2021, 100, 119.e7-119.e13.	1.5	19
41	Spastic ataxias. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2018, 155, 191-203.	1.0	18
42	Characterization of a novel SPG3A deletion in a French-Canadian family. Annals of Neurology, 2007, 61, 599-603.	2.8	17
43	POLR3A variants in hereditary spastic paraplegia and ataxia. Brain, 2018, 141, e1-e1.	3.7	17
44	The influence of vascular risk factors on cognitive function in early Parkinson's disease. International Journal of Geriatric Psychiatry, 2018, 33, 288-297.	1.3	17
45	An Optimized Approach to Recover Secreted Proteins from Fibroblast Conditioned-Media for Secretomic Analysis. Frontiers in Cellular Neuroscience, 2016, 10, 70.	1.8	16
46	Physician-assisted death. Neurology, 2016, 87, 1152-1160.	1.5	16
47	Sequencing of the GBA coactivator, Saposin C, in Parkinson disease. Neurobiology of Aging, 2018, 72, 187.e1-187.e3.	1.5	16
48	Smoking history is associated to cognitive impairment in Parkinson's disease. Aging and Mental Health, 2017, 21, 322-326.	1.5	13
49	Medical and Paramedical Care of Patients With Cerebellar Ataxia During the COVID-19 Outbreak: Seven Practical Recommendations of the COVID 19 Cerebellum Task Force. Frontiers in Neurology, 2020, 11, 516.	1.1	13
50	Variants in the Niemannâ€“Pick type C gene NPC1 are not associated with Parkinson's disease. Neurobiology of Aging, 2020, 93, 143.e1-143.e4.	1.5	13
51	Genome-wide association analysis identifies new candidate risk loci for familial intracranial aneurysm in the French-Canadian population. Scientific Reports, 2018, 8, 4356.	1.6	12
52	Recessive cerebellar and afferent ataxias â€" clinical challenges and future directions. Nature Reviews Neurology, 2022, 18, 257-272.	4.9	12
53	TOX3 Variants Are Involved in Restless Legs Syndrome and Parkinsonâ€™s Disease with Opposite Effects. Journal of Molecular Neuroscience, 2018, 64, 341-345.	1.1	11
54	Evidence for Nonâ€Mendelian Inheritance in Spastic Paraplegia 7. Movement Disorders, 2021, 36, 1664-1675.	2.2	11

#	Article	IF	Citations
55	Paresthesia and sensory disturbances associated with 2009 pandemic vaccine receipt: Clinical features and risk factors. Vaccine, 2015, 33, 4464-4471.	1.7	9
56	Association study of essential tremor genetic loci in Parkinson'sÂdisease. Neurobiology of Aging, 2018, 66, 178.e13-178.e15.	1.5	9
57	Current and Promising Therapies in Autosomal Recessive Ataxias. CNS and Neurological Disorders - Drug Targets, 2018, 17, 161-171.	0.8	9
58	Genetic testing for amyotrophic lateral sclerosis in Canada â€“ an assessment of current practices. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2021, , 1-8.	1.1	9
59	LRRK2 is not a Significant Cause of Parkinson's Disease in French-Canadians. Canadian Journal of Neurological Sciences, 2007, 34, 333-335.	0.3	8
60	Functional alterations in large-scale resting-state networks of amyotrophic lateral sclerosis: A multi-site study across Canada and the United States. PLoS ONE, 2022, 17, e0269154.	1.1	8
61	Biofabrication of a three dimensional humanâ€based personalized neurofibroma model. Biotechnology Journal, 2021, 16, e2000250.	1.8	7
62	Distinct patterns of progressive gray and white matter degeneration in amyotrophic lateral sclerosis. Human Brain Mapping, 2022, 43, 1519-1534.	1.9	7
63	Genetic, structural and clinical analysis of spastic paraplegia 4. Parkinsonism and Related Disorders, 2022, 98, 62-69.	1.1	7
64	Case Report: Acute Necrotizing Encephalopathy Following COVID-19 Vaccine. Frontiers in Neurology, 2022, 13, 872734.	1.1	7
65	A National Spinal Muscular Atrophy Registry for Real-World Evidence. Canadian Journal of Neurological Sciences, 2020, 47, 810-815.	0.3	6
66	Goal management training and psychoeducation / mindfulness for treatment of executive dysfunction in Parkinsonâ€™s disease: A feasibility pilot trial. PLoS ONE, 2022, 17, e0263108.	1.1	6
67	Persisting chemosensory impairments in 366 healthcare workers following COVID-19: an 11-month follow-up. Chemical Senses, 2022, 47, .	1.1	6
68	RIC3 variants are not associated with Parkinson's disease in French-Canadians and French. Neurobiology of Aging, 2017, 53, 194.e9-194.e11.	1.5	5
69	No rare deleterious variants from STK32B , PPARGC1A , and CTNNA3 are associated with essential tremor. Neurology: Genetics, 2017, 3, e195.	0.9	5
70	Environmental risk factors for amyotrophic lateral sclerosis: a caseâ€“control study in Canada and France. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2022, 23, 592-600.	1.1	5
71	Altered Theory of Mind in Parkinsonâ€™s Disease and Impact on Caregivers: A Pilot Study. Canadian Journal of Neurological Sciences, 2022, 49, 437-440.	0.3	4
72	Goal management training Â® home-based approach for mild cognitive impairment in Parkinsonâ€™s disease: a multiple baseline case report. Neurocase, 2018, 24, 276-286.	0.2	3

#	Article	IF	Citations
73	Genetic and Epidemiological Study of Adult Ataxia and Spastic Paraplegia in Eastern Quebec. Canadian Journal of Neurological Sciences, 2021, 48, 655-665.	0.3	3
74	CAPTURE ALS: the comprehensive analysis platform to understand, remedy and eliminate ALS. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2022, , 1-7.	1.1	3
75	Absence of Mutation Enrichment for Genes Phylogenetically Conserved in the Olivocerebellar Motor Circuitry in a Cohort of Canadian Essential Tremor Cases. Molecular Neurobiology, 2019, 56, 4317-4321.	1.9	2
76	The Puzzle of Huntington Disease Phenocopies. JAMA Neurology, 2016, 73, 1056.	4.5	1
77	<scp>KCNA2</scp> mutations are rare in hereditary spastic paraplegia. Annals of Neurology, 2017, 81, 325-326.	2.8	0